Navigation Links
Santaris Pharma presents positive preclinical data on SPC2996 at,the American Association for Cancer Research

>The protein Bcl-2, first identified in B-cell lymphoma/leukaemia cells from which its name derives, is one of a family of intracellular proteins regulating cell survival and cell death. Some types of cells in the body, for example blood cells, are programmed to die after a few weeks of life, in the case of blood cells to be replaced in the circulation by fresh cells produced in the bone marrow. This process of programmed cell death is known as apoptosis. Bcl-2 is an apoptosis suppressor protein, i.e. it extends the lifespan of the cell in the presence of normal apoptosis stimuli. The levels of Bcl-2 within the cell are frequently over-expressed in malignant cancers, and this is particularly the case in human chronic lymphocytic leukaemia and lymphoma where it acts to prolong the life of malignant white blood cells. Drugs which lower the concentration of Bcl-2 or inhibit its function may therefore have therapeutic benefit by inducing cancer cell death and removal without resorting to chemotherapy.

About SPC2966

SPC2996 is the first of a portfolio of novel experimental drugs blocking harmful gene expression being designed and developed by Santaris Pharma. The drug belongs to a new class of drugs called RNA Antagonists, proprietary to Santaris Pharma, based on the novel three-dimensional analogue of RNA known as Locked Nucleic Acid (LNA). The drug binds with high potency and specificity to the messenger RNA for Bcl-2 and destroys it within the cell, resulting in a reduction in Bcl-2 protein concentration. SPC2996 is an investigational product which has not yet been approved by any regulatory agency as effective or safe for patient use but the novel agent is currently being evaluated in international Phase I/II studies in human CLL in centres in Denmark, France, UK and the USA.

AACR Abstract

An Abstract of the work described in this release can be found on the American Association for Cancer Research (AACR) 2007 Annual Meeting database at th
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Santaris Pharma Presents Positive Clinical Data on SPC2996 in Chronic Lymphocytic Leukaemia
2. Sygnis Pharma AG announces date for presentation of clinical results
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
Post Your Comments:
(Date:1/15/2014)... 2014  According to Millennium Research Group (MRG), the ... the United States and European ... expand moderately through 2022, with embolization particles representing ... interest in drug-eluting beads (DEBs) and radioembolization spheres ...
(Date:1/15/2014)... Pharmaceuticals International, Inc. (NYSE: VRX and ... the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("HSR") with ... indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ("Purchaser"), for all ... Medical, Inc. (NASDAQ: SLTM ) ("Solta") at ...
(Date:1/15/2014)... 2014  Zafgen, Inc., a leading biopharmaceutical company dedicated ... patients, today announced initial results from its Phase ... methionine aminopeptidase 2 (MetAP2), in patients with Prader-Willi ...  These results showed improvements in body weight, hunger-related ...
Breaking Medicine Technology:US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
... K-V Pharmaceutical Company (NYSE:  KVa/KVb) (the "Company") today announced that ... U.S. Healthcare II, L.L.C. (together the "Lenders") that grant Lenders ... Company,s Class A Common Stock, par value $.01 per share ... second warrant to Lenders that grants Lenders the right to ...
... /PRNewswire-Asia-FirstCall/ -- China Medical Technologies, Inc. (the "Company") (Nasdaq: ... diagnostic ("IVD") company, today announced its unaudited financial results ... ("2Q FY2010"). 2Q FY20 10 ... increased by 21.5% year-over-year to RMB201.8 million (US$30.2 million). ...
Cached Medicine Technology:K-V Pharmaceutical Company Announces Reliance on Financial Distress Exception to NYSE's Shareholder Approval Policy 2K-V Pharmaceutical Company Announces Reliance on Financial Distress Exception to NYSE's Shareholder Approval Policy 3K-V Pharmaceutical Company Announces Reliance on Financial Distress Exception to NYSE's Shareholder Approval Policy 4K-V Pharmaceutical Company Announces Reliance on Financial Distress Exception to NYSE's Shareholder Approval Policy 5K-V Pharmaceutical Company Announces Reliance on Financial Distress Exception to NYSE's Shareholder Approval Policy 6K-V Pharmaceutical Company Announces Reliance on Financial Distress Exception to NYSE's Shareholder Approval Policy 7K-V Pharmaceutical Company Announces Reliance on Financial Distress Exception to NYSE's Shareholder Approval Policy 8K-V Pharmaceutical Company Announces Reliance on Financial Distress Exception to NYSE's Shareholder Approval Policy 9K-V Pharmaceutical Company Announces Reliance on Financial Distress Exception to NYSE's Shareholder Approval Policy 10China Medical Technologies Reports Second Fiscal Quarter Financial Results 2China Medical Technologies Reports Second Fiscal Quarter Financial Results 3China Medical Technologies Reports Second Fiscal Quarter Financial Results 4China Medical Technologies Reports Second Fiscal Quarter Financial Results 5China Medical Technologies Reports Second Fiscal Quarter Financial Results 6China Medical Technologies Reports Second Fiscal Quarter Financial Results 7China Medical Technologies Reports Second Fiscal Quarter Financial Results 8China Medical Technologies Reports Second Fiscal Quarter Financial Results 9China Medical Technologies Reports Second Fiscal Quarter Financial Results 10China Medical Technologies Reports Second Fiscal Quarter Financial Results 11China Medical Technologies Reports Second Fiscal Quarter Financial Results 12China Medical Technologies Reports Second Fiscal Quarter Financial Results 13China Medical Technologies Reports Second Fiscal Quarter Financial Results 14
(Date:4/17/2014)... By discovering a new mechanism that allows blood ... at UC Irvine and the Salk Institute have opened ... prevent stroke-induced brain damage. , A complex and devastating ... and primary reason for disability in the U.S. The ... lets blood-borne material into the brain, causing the permanent ...
(Date:4/17/2014)... Alliance, a nonprofit organization that focuses on conservation and ... examining the current state of knowledge of the deadly ... global surveillance strategies to combat the emergence of infectious ... West Africa that has claimed the lives of 122 ... According to the World Health Organization (WHO), the deadly ...
(Date:4/17/2014)... Spending time online has the potential to ward off ... according to research published online in The ... Sciences . In the article " Internet Use ... States: A Longitudinal Analysis ," the authors report that ... by 33 percent among their study sample. , ...
(Date:4/17/2014)... scientists and their partners have found that their proprietary ... transmission of multiple sexually transmitted infections (STIs) in both ... virus 2 (HSV-2), and human papillomavirus (HPV). The USAID-funded ... is effective against multiple strains of HIV, and has ... three viruses of at least eight hours prior to ...
(Date:4/17/2014)... 17, 2014 Meaningful long-term survival is possible ... the abdomen when treated with cytoreductive surgery with ... first-of-its-size analysis by physicians at Wake Forest Baptist ... largest reported, single-center experience with cytoreductive surgery and ... and analysis of 20 years, worth of patient ...
Breaking Medicine News(10 mins):Health News:Study IDs new cause of brain bleeding immediately after stroke 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3Health News:Internet use may cut retirees' depression 2Health News:Animal study provides first evidence that gel can prevent multiple virus transmission in vagina/rectum 2Health News:20 years of data shows treatment technique improvement for advanced abdominal cancer 2
... homeless population among New Yorkers are more prone to go ... the population. // Detox centers will be established at some ... on the rise. Rapid HIV testing for women who are ... the Health Department. ,A large number of ...
... Copeman Healthcare of Canada has been warned of fines by ... insured health services. Copeman Healthcare intends to establish clinics in ... it will be charging a joining fee of $1,200, and ... ,The medicare law of the state says ...
... worst hit by AIDS. But now after bringing in changes in ... the initial sex // and using condoms have greatly reduced the ... ,It was found that among women in the age group of ... was witnessed among men in the age group of 17-29. ...
... model has been developed that can predict the occurrence of ... mild or severe can be told five months before it ... emergency measures to be done in advance. ,The ... officials these days. ,The problem is greatest ...
... by a House of Lords committee has revealed that 90 ... tested on them. Dangerous drugs like morphine, // thyrozine, the ... the treatment of children even though there was no valid ... ,The report also alleges that some high-risk medications like asthma ...
... recruit 50,000 people as a part of a large study called ... between lifestyle and genetics as regards the health of an individual. ... and is one of the largest healthcare projects in the UK. ... of information so that it would be easy to assess who ...
Cached Medicine News:Health News:Prediction of malaria epidemics possible! 2
... Volk's super series ... lenses. Variable retinal ... unprecedented fundus diagnostic ... maximum potential field ...
Volk indirect lenses. Wide field retinal diagnosis & treatment....
Volk indirect lenses. High magnification views of the posterior pole....
... This contact class is particularly ... lamps which have a smaller ... the reduction prism than the ... fundus / iridocornea. Mirror angle ...
Medicine Products: